Global Influenza Diagnostics Market is valued at approximately USD 1.63 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.78% over the forecast period 2024-2032. Influenza diagnostics refers to the methods and tools used to identify and diagnose influenza virus infections in individuals. These diagnostics play a crucial role in public health, allowing for early detection, treatment, and prevention of the spread of influenza. Also, the market was witnessing advancements in diagnostic technologies, particularly in the development of Rapid Diagnostic Tests (RDTs) and molecular diagnostics. These advancements aimed to improve the accuracy, sensitivity, and speed of influenza diagnosis which anticipated to support the growth of Influenza Diagnostics Market.
Moreover, increased awareness about the severity of influenza and its potential to cause outbreaks and pandemics has driven governments, healthcare organizations, and individuals to invest in diagnostic measures for timely detection and containment. Also, with the rise in the number of influenza cases globally, there is a growing demand for efficient and accurate diagnostic tests to identify and manage the infection. Additionally, other factors that support the market growth are the increasing geriatric population, growing demand for point-of-care testing, and cohesive government initiatives and funding. However, the lack of skilled professionals, and stringent regulatory frameworks are anticipated to hinder the market growth during the forecast period 2024-2032.
The key regions considered for the global Influenza Diagnostics market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market. Increasing awareness among healthcare professionals and the general public about the importance of early diagnosis and treatment of influenza fuels the demand for diagnostic tests. Awareness campaigns by healthcare organizations and government bodies contribute to this trend. Also, North America has a significant healthcare expenditure budget, enabling healthcare facilities to invest in advanced diagnostic technologies. This financial capacity facilitates the adoption of innovative influenza diagnostic solutions. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period 2024-2032.
Major market player included in this report are:
3M Company
Abbott Laboratories
Becton, Dickinson and Company (BD)
Meridian Bioscience, Inc.
Quidel Corporation
F. Hoffmann-La Roche Ltd
SA Scientific Ltd
SEKISUI Diagnostics
Thermo Fisher Scientific, Inc.
Hologic, Inc.
The detailed segments and sub-segment of the market are explained below:
By Test Type
RIDT
RT-PCR
Cell Culture
Others
By End Use
Hospitals
POCT
Laboratories
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
